World's Premier Precision Health Intelligence Platform
The intelligence infrastructure powering the global longevity economy — from genomics to gut microbiome, wearables to biological age. The "Intel Inside" of precision health.
600K+ Users · 14 CountriesB2B(2C) Platform20+ Enterprise ClientsLaunch in <90 Days
Why LifeNome
A $62B Market at Inflection
Three macro tailwinds are converging to create the largest consumer health opportunity since genomics — and brands need a faster way to serve it.
Aging Population
$62B
Longevity & precision health market by 2029
34% of Americans are 50+ and the majority will manage chronic disease after 65. Prevention is the only scalable answer.
Personalization Wave
270%
Adherence lift: personalized vs. generic
57% of US consumers are willing to share biological and wearable data for personalized health. Adherence to lifestyle changes over 6 months is 270% higher.
Industry Boom
2,000+
Longevity companies & clinics
Across North America, the Middle East and Latin America, with an estimated $4.4B of PE and venture investment globally. Longevity biomarkers grew 870%+ annually from 2020–24.
The Problem LifeNome Solves for Brands
15.2mo
Avg time to market for a precision health MVP
$3.2M+
Avg cost of precision health MVP development
100+
New longevity papers published monthly
LifeNome delivers: <90 days to market · as little as $50K for an MVP · the most comprehensive choice of biomarkers in the market
Market sizing source: PA Consulting (2023)
Platform
Precision Health Intelligence Platform
The "Intel Inside" of precision health — an end-to-end intelligence platform that partners embed to power their precision health products in weeks, not years.
Blood + epigenetic clocks + imaging + physiological + actuarial — cross-validated in one platform
Nonlinear Biomarker Interactions
ML engine models cross-domain risk amplification invisible to linear analysis
Patented Smartphone Imaging
Facial age, body composition, grip strength — no lab required
White-Label B2B API
Built for enterprise deployment, with SDKs and fully branded apps
Solutions
Precision Health AI Engines
Five vertical engines, each delivered as lab testing, needs assessments, user-facing applications, personalized products and programs, and outcome monitoring.
Precision Longevity
Healthy Aging (50+) Platform
Athletic Performance Optimization
Longevity for Hospitality
Precision Health for Smart Homes
Precision Nutrition
Personalized Weight Loss
GLP-1 Companion Application
Personalized Supplementation
Chronic Disease Management
Precision Women's Health
Fertility nutrition & supplementation
Pregnancy nutrition, exercise & supplementation
Menopause nutrition & supplementation
Hormonal health optimization
Precision Beauty
Anti-aging skin care formulation
Personalized hair loss treatment optimization
Beauty & skin care product recommendation (e-commerce)
Precision Medicine
Disease screening & preventive health
Pharmacogenomics
Population health
Health accessibility
Ready-to-Launch Platforms
Branded platforms partners can deploy or co-develop.
Precision Longevity
Precision Health Intelligence Platform
Precision Beauty
Blueprint Beauty™SkinGevity™
Precision Women's Health
Nine.Moons™MenoGevity™
Spotlight: SkinGevity™
The first platform to transform visible results and product claims into measurable biological rejuvenation.
• Combines epigenetic biomarkers, facial imaging and AI modeling to quantify skin longevity.
• Enables reproducible before-and-after testing to demonstrate measurable rejuvenation.
Health Intelligence
Health Indices & Wellness
396 assessment tools — 212 actionable health indices across 13 wellness verticals, plus 184 personalized wellbeing traits — ready to embed in any partner product.
Calibrated against established models such as ASCVD, Framingham and Finnish T2D.
Exome+ Conditions by Specialty (3,096)
OMIM-curated definitions for molecular diagnosis and carrier screening.
Pharmacogenomics: 192 Medications
Genetic predictors of efficacy and toxicity for precision dosing, drug selection and adverse-event risk stratification.
Cardiovascular
ACE inhibitors & ARBs
Beta-blockers
Statins & lipid agents
Anticoagulants
Neuropsychiatric
Antidepressants
Antipsychotics
Anxiolytics
Mood stabilizers
Metabolic & Anti-inflammatory
Diabetes medications
NSAIDs & analgesics
Gout agents
Biologics & immunosuppressants
Oncology & Antimicrobial
Cancer therapeutics
Antibiotics
Antivirals
Antifungals
Sample Pharmacogenomic Applications
Medication
Class
Clinical Application
Warfarin
Anticoagulant
CYP2C9 & VKORC1 genotyping for dose and INR target prediction
Clopidogrel
Antiplatelet
CYP2C19 loss-of-function assessment for therapeutic response
Metoprolol
Beta-blocker
CYP2D6 phenotyping for dose optimization
Fluoxetine / Paroxetine
SSRI antidepressant
CYP2D6 & CYP2C19 guided dosing
Codeine
Analgesic
CYP2D6 phenotype assessment (avoid in poor metabolizers)
Data Foundation
Validated on Population-Scale Data
Lifenome's risk models and health indices are calibrated and validated against an integrated, multi-modal dataset spanning four population cohorts and eight data modalities.
1.75–2.0M
Cumulative Individuals*
4
Calibration Cohorts
8
Data Modalities
0.778
Mortality C-Index (UK Biobank)
UK Biobank
500,000+
Participants aged 37–73 in the UK · 10+ years of longitudinal mortality follow-up · 25–57 circulating biomarkers
NIH All of Us
1,000,000+
Target cohort in the US · >75% oversampling of historically underrepresented populations · EHR, survey, biosample, genotyping and wearable data
Emirati Genome Project
Regional
Gulf Arab genetic representation · region-specific variant and ancestry calibration for the Middle East
1000 Genomes + LatAM Wearables
Regional
Peruvian, Colombian and Mexican ancestry · real-time activity, heart rate and behavioral data from Latin American cohorts
*Cumulative total is an estimate based on public genome project sizes and projected LatAM wearables integration.
Eight Integrated Data Modalities
A. Genomic
WGS, exome and genotyping arrays; medical, nutrition, skincare, fitness and wellbeing PGS; 193 PGx traits; APOE and neurodegeneration scores
B. Proteomic
Circulating blood protein biomarkers; plasma proteomics; cardiovascular, metabolic, immune and inflammatory signatures
C. Metabolomic
Lipid profiles, amino acids, organic acids, vitamin and mineral levels, inflammatory and kidney/liver markers
D. Epigenetic
DNA methylation clocks (Hannum, Horvath, PhenoAge, DunedinPACE); >500,000 CpG sites
E. Wearable & Sensor
PPG-derived HR/HRV, optical body composition, Apple Health / Google Fit / smartwatch integration
F. Lifestyle & Behavioral
Diet, exercise, sleep, stress, smoking/alcohol, chronotype; regional lifestyle data
G. Clinical & EHR
ICD-10 diagnoses, medication history linked to PGx, procedures, longitudinal labs
High confidence: European, African-American and Hispanic/Latino populations.
Moderate confidence: Middle Eastern, South Asian and East Asian populations (Emirati and 1000 Genomes calibration).
Expanding: Latin American coverage via wearables integration, plus ongoing work to extend PGx and epigenetic clock validation to non-European ancestries and to broaden Asian, Sub-Saharan African, Pacific Islander and Indigenous representation.
Global Reach
Proven Across 14 Countries
Product-market fit established across four enterprise segments, with regional partnerships that put Lifenome technology in front of hundreds of thousands of end users.
600K+
End-Users & Patients Served
Across 14 countries
20+
Enterprise Customers
Multi-year agreements
4
Client Segments
Since 2018
3
Business Models
Licensing · Rev share · JV
UAE & Middle East
Emirati Genome
• 600K+ reports generated
• Expansion plans for a longevity platform for all UAE citizens and expats
Mexico & LATAM
Genetria
• Spun off with Lifenome® Genomics AI® technology
• Joint venture with Optimo Life targeting the $11B LatAm precision longevity and beauty market
Singapore & SE Asia
Pathomics Health
• Precision health and longevity agreement for Southeast Asia
• Revenue-share agreement for direct-to-consumer and employee wellness offerings
CB Insights "Outperformer"
Named among the top 15 precision health companies globally
Partners & Clients
Powering the Global Longevity Ecosystem
Trusted by the global longevity industry and built for scalability (2018–present). Our B2B(2C) partners span four segments and work with us through volume-based licensing, revenue share and joint ventures.
Longevity Enterprises
LG Electronics
Genetria
Forté
Healthspan Digital
Zurich
Precision Health & Genomics Companies
M42 / Emirati Genome
Vitel Health
Pathomics Health
Asia Genomics
Nutrition, Fitness & Wellness Enterprises
PepsiCo
Campbell's
GNC
AWA Nutrition
Consumer Health & Beauty Enterprises
Biologique Recherche
Allergan
Science Humans
Happy Head
SuperNatural Skincare
Business modelsVolume-based licensingRevenue shareJoint ventures (equity share)
Differentiation
Platform vs. Point Solutions
LifeNome is not competing with InsideTracker or Function Health for consumer bloodwork. LifeNome is the intelligence infrastructure that enables those platforms — and any health company — to build multi-omics AI analytics.
Capability
LifeNome
InsideTracker
Function Health
ChatGPT/LLM
Blood Biomarker Analysis
229 markers + ML interactions
48 markers
160+ markers
Text only
DNA / Polygenic Risk Scores
215 disease + 184 wellbeing + 192 PGx
261 SNPs, 38 traits
None
None
Epigenetic / Methylation Clocks
4 clocks + 500K+ CpG sites
N/A
N/A
N/A
Microbiome Analysis
86 taxa + diversity + pathways
N/A
N/A
N/A
Smartphone Camera Imaging
Patented facial age + body comp
N/A
MRI/CT add-on ($499+)
N/A
White-Label B2B API
Full enterprise white-label
Consumer only
Consumer only
Partial
Pharmacogenomics (PGx)
192 medications, CYP2D6/2C19
N/A
N/A
N/A
Specialized Vertical AI Engines
13 verticals, 212 health indices
10 healthspan scores
Per-biomarker flags
None
01
1,000+ Biomarkers
The most comprehensive choice of biomarkers in the market, kept current with a fast-moving science.
02
Launch in <90 Days
Initial go-to-market in under 90 days, versus a 15.2-month industry average.
03
MVP from $50K
As little as $50K to a working MVP, versus $3.2M+ average build cost.
Team
World-Class Scientists
A founding team of top-cited scholars, supported by ten scientific and technology advisors with 200K+ collective peer-reviewed citations.
CEO
Ali Mostashari, PhD
MIT PhD · Top 20 globally cited in Complexity Science · Research Affiliate Scholar, MIT · Advised Fortune 500s, WEF, ANR and Newsweek on AI and healthcare · Oversaw a $1.2B tech portfolio in Africa
Chief Scientist
Raya Khanin, PhD
Weizmann PhD · Top 10 globally cited in Computational Genomics · Faculty at Memorial Sloan Kettering · Dorothy Hodgkin Fellow (UK) · 50+ publications · 16K+ citations
SVP Technology
Mario Storga, PhD
University of Bath Postdoc · Top 20 globally cited in Semantic Networks · Professor at University of Zagreb · Chair of Design Society and MAE at FSB/UZ
Science & Technology Advisory Team
Klemo Vladimir, PhD
VP Computational Science · Professor of Computer Science · AI/ML for large datasets
Marija Majda, PhD
Senior Computational Scientist · Computational biology & predictive ML
Keshav Singh, PhD
Senior longevity advisor · Top cited longevity scholar · Mitochondrial DNA expert
Ana Maria Siega-Riz, PhD
Senior women's health advisor · Dean, School of Public Health, UMass Amherst
Nicole Avena, PhD
Senior medical advisor · Prof. of Neuroscience, Mount Sinai & Princeton
Poroshat Shekarloo, MD
Chief Medical Advisor · Director of Peer Review, Maimonides Medical Center
Sanaz Nosrat, PhD
Senior exercise-for-longevity scientist · Prof. of Exercise Physiology, Columbia
Martin Gershon, MD, PhD
Senior healthcare strategy advisor · Senior Advisor to Cancer Moonshot, White House
Delaram Kahrobaei, PhD
Senior AI & quantum computing · Prof. of Computer Science, CUNY
Martin Tristani, MD, PhD
Medical science advisor · Board-certified cardiologist, University of Minnesota
200K+
Collective Citations
10
Advisors
3
Founding Scientists
Partner With Us
Bring Precision Health to Your Customers
LifeNome is not a health app. It is the intelligence layer that makes precision health possible at scale — embedded in your brand, live in as little as 90 days.
Volume-Based Licensing
License the platform, reports and APIs on a volume basis to power your own precision health products.
Revenue Share
Launch with lower upfront cost and share in the revenue your precision health offering generates.
Joint Venture
Co-build a new venture around Lifenome technology in your market, with shared equity.